溢多利(300381.SZ)擬斥500萬元收購雲南楚麻生物科技96%股權
格隆匯10月18日丨溢多利(300381.SZ)公佈，公司(“甲方”)是應用現代生物技術，立足於生物產業，致力於生物藥品、生物酶製劑、植物提取物、功能性飼料添加劑等產品研發、生產、銷售和服務，以及為客户持續提供生物技術解決方案、生物提取技術的專業生物技術企業。雲南楚麻生物科技有限公司(“標的公司”)成立於2019年3月18日，是一家註冊資本為人民幣5000萬元的主要從事大麻種植與研究的公司，珠海泰克諾利生物科技有限公司(“泰克諾利”或“乙方”)持有其100%股權。為充分發揮公司的資金優勢與植物提取技術優勢，公司決定收購泰克諾利持有的標的公司96%股權，甲乙雙方於2019年10月18日在雲南省昆明市簽訂了《關於廣東溢多利生物科技股份有限公司收購雲南楚麻生物科技有限公司96%股權的框架協議》，經雙方初步協商同意，交易價格為500萬元。
協議顯示，乙方同意將其持有的標的公司96%股權(“標的股權”)轉讓給甲方。甲乙雙方經友好協商一致同意，在符合協議“股權轉讓的實施”約定條款時，甲方以500萬元收購乙方持有的標的股權公司96%股權。該框架協議簽署後，甲方聘請評估機構對標的股權進行評估，實際交易價格以評估價作為參考。此次收購完成後，標的公司的股權結構為：甲方佔96%，乙方佔4%。
公司是應用現代生物技術，立足於生物產業，致力於生物藥品、生物酶製劑、植物提取物、功能性飼料添加劑等產品研發、生產、銷售和服務，以及為客户持續提供生物技術解決方案、生物提取技術的專業生物技術企業。雲南楚麻生物科技有限公司主要從事大麻的種植、研究，擁有云南省工業大麻種植許可證。公司收購標的公司後，可將公司的資金優勢、植物提取技術優勢與標的公司的工業大麻種植、加工技術相整合，加強公司植物提取物板塊業務發展，形成資源互補、合作共贏的良好局面，符合公司發展戰略，有利於拓寬公司產品線，提升公司綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
